EDS ECHO Pediatrics North America Application

EDS ECHO Pediatrics North America

This is a free program for healthcare professionals worldwide, across all disciplines who want to improve their ability to care for children and younger people with EDS, HSD and associated symptoms and conditions.

Please complete the application form below to apply for a place on the EDS ECHO Pediatrics North America Program.

EDS ECHO Pediatrics North America – Program Details:

Applications are now open for the EDS ECHO Pediatrics North America program, which will commence in April 2022.

EDS ECHO Pediatrics is a free program for Healthcare Professionals worldwide, across all disciplines who want to improve their ability to care for children and younger people with EDS, HSD, and associated symptoms and conditions.

The programs consist of expert presentations and case-based interactive sessions delivered virtually via the Zoom platform. Each session is 1hr in length and are led by Dr. Sarah Schwartz and Constance O’Connor.

 Program: EDS ECHO Pediatrics North America Clinical Lead: Dr. Sarah Scwartz and Ms Constance O’Connor
Date & Time: Tuesdays, 12:00pm – 1:00pm Eastern Time (US & Canada)
 Session 1 – Hypermobility in the Pediatric Population April 5, 2022
Session 2 – Diagnosis of EDS: Clinical Criteria and Genetic Testing April 12, 2022
 Session 3 – Physiotherapy Approaches to the Management of Hypermobility and EDS April 19, 2022
 Session 4 – Pain Management in Hypermobility and EDS April 26, 2022
 Session 5 – Psychological and Social Concerns in EDS May 3, 2022
 Session 6 – Cardiovascular Concerns and Management in Hypermobility and EDS May 10, 2022
 Session 7 – GI Issues and Management in Hypermobility and EDS May 17, 2022
 Session 8 – Neurological Assessment and Management in Hypermobility and EDS May 24, 2022
 Session 9 – Panel Discussion May 31, 2022


PLEASE NOTE – Session dates and topics are subject to change.

The program content is currently only presented in English.

This is a virtual program, you will be sent a link to join the sessions which are run via the zoom platform. Once signed up, we ask that you attend a minimum of 5 out of the 9 sessions. You can catch up with the sessions you miss by watching our password protected recordings online. For all queries regarding EDS ECHO, please email our EDS ECHO Program Coordinator.

Each EDS ECHO session is worth 1.0 CME/CEU/CE credit per 60 minutes of live session learning.

For more information, visit our dedicated EDS ECHO Pediatrics web page.

Please complete and submit the following information to apply for a place on the program:

This program is now full and applications are closed.

In support of improving patient care, this activity has been planned and implemented by The Ehlers-Danlos Society and Project ECHO®.  Project ECHO® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

EDS ECHO

AMA Designation Statement
Project ECHO® designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™ per 60 minutes. Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement
Project ECHO®, in compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, requires that anyone who is in a position to control the content of an educational activity disclose all relevant financial relationships they have had within the last 24 months with an ineligible company.

None of the planners and presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Alan Hakim, MD; Stacey Simmonds; Paul Gardener; Owen Moore; Lara Bloom, Prof; Jane Schubart, MD; Rebecca Bascom, MD; Shani Weber; Sarah Schwartz, MD, Connie O’Connor;

The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company:

Nature of Relationship Name of Ineligible Company
Dr. Clair Francomano Consultant
Other Financials

Acer Therapeutics
Scientific Advisory Board, Kyani International

All of the relevant financial relationships listed for [this/these individual(s)] have been mitigated.